Concert Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
LEXINGTON, MASS. — Concert Pharmaceuticals, Inc.™, the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today that it will be presenting at the 26th Annual JPMorgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco. Roger Tung, Ph.D., President and Chief Executive Officer of CoNCERT, will provide an overview of the Company on Monday, January 7, 2008 at 2:00 p.m. (PT).
CoNCERT Pharmaceuticals is the first company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. CoNCERT applies its innovative precision chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. CoNCERT expects to initiate its first clinical study in 2008. More information on CoNCERT can be found on the Company’s website at http://www.concertpharma.com.